Y2020

New economic models for antibiotics: Are we there yet? No, but we ARE on the road

Dear All, The Duke-Margolis team hosted an excellent full-day workshop on 16 Jan 2020. Entitled “Exploring Opportunities to Reform Antimicrobial Payment and Post-Market Incentives” and chaired by Mark McClellan, the workshop’s outstanding cast of presenters and discussants provided a thorough discussion of both the need for new payment models and and the many ongoing activities focused

Read More »

WHO Review of the Preclinical and Clinical Antibacterial Pipeline

Dear All, WHO has today released two exhaustive reviews of the antibacterial R&D universe (and by way of full disclosure, let me say upfront that I participated in the clinical pipeline discussion): The preclinical pipeline (link) This one includes a fascinating data-mining tool that explores the 252 antibacterial products being developed in 145 institutions around the

Read More »

CC4CARB solicitation is out (16 Mar 2020 deadline) / Superb WSJ podcast on antibiotic economics

Dear All, I wrote on 3 Jan 2020 (link) about the NIAID contract intended to establish an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). The formal solicitation has now gone live and can be found here. The deadline for applications is 16 Mar 2020. Get to it! In parallel, there is a superb Wall Street Journal podcast dated 13 Jan 2020 about

Read More »

Japan’s antibacterial R&D landscape / Japan calls for Pull incentives

Dear All: Late last year, I had the opportunity to hear a presentation on antibiotic R&D in Japan by Norio Ohmagari. Based in Tokyo at the National Center for Global Health and Medicine Hospital (link), Norio is Director of its (i) AMR Clinical Reference Center, (ii) Disease Control and Prevention Center, and (iii)  WHO Collaborating

Read More »

NIAID/DMID seeks contract proposals for AMR / 9 Apr 2020 deadline

Dear All, As part of a NIAID Omnibus Broad Agency Announcement (BAA) posted on 31 Dec 2019, NIAID’s Division of Microbiology and Infectious Diseases (DMID, link) has three research areas (RAs) soliciting contract proposals for preclinical and clinical development of vaccines, therapeutic, and diagnostics for microbial pathogens. The entire BAA can be found here. The three RAs

Read More »

NIAID to fund a Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB)

Dear All, Warm up your chemistry set! NIAID has just released a pre-solicitation notice of their intent to request applications for a new NIAID contract intended to establish an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). NIAID anticipates awarding a single CC4CARB contract funding 28,000 direct labor hours per year for up to 5 years. The core

Read More »

Melinta goes bankrupt / Never let a good crisis go to waste

Dear All (long-ish, wonk-ish note alert … lots of details to absorb): This newsletter has a followup here. Sadly, Melinta Therapeutics, Inc. declared bankruptcy just before the end of 2019 (link). Formerly known as Rib-X (link), Melinta went public in 2017 through a reverse merger with Cempra (link); and via a series of deals had four

Read More »
Scroll to Top